[1] Mikhail M, Wang B, Saksena NK. Mechanisms involved in non-progressive HIV disease. AIDS Rev, 2003; 5, 230-44.
[2] Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis, 2009; 200, 1714-23. doi:  10.1086/599183
[3] Okulicz JF, Lambotte O. Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS, 2011; 6, 163-8. doi:  10.1097/COH.0b013e328344f35e
[4] Kaufman J, Jing J. China and AIDS--the time to act is now. Science, 2002; 296, 2339-40. doi:  10.1126/science.1074479
[5] Zhang L, Chen Z, Cao Y, et al. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. J Virol, 2004; 78, 13591-9. doi:  10.1128/JVI.78.24.13591-13599.2004
[6] Li Z, He X, Wang Z, et al. Tracing the origin and history of HIV-1 subtype B' epidemic by near full-length genome analyses. AIDS, 2012; 26, 877-84. doi:  10.1097/QAD.0b013e328351430d
[7] Gurdasani D, Iles L, Dillon DG, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS, 2014; 28, 149-62. doi:  10.1097/QAD.0000000000000049
[8] van der Helm JJ, Geskus R, Lodi S, et al. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. Lancet HIV, 2014; 1, e41-8. doi:  10.1016/S2352-3018(14)70016-5
[9] Blankson JN, Bailey JR, Thayil S, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol, 2007; 81, 2508-18. doi:  10.1128/JVI.02165-06
[10] O'Connell KA, Brennan TP, Bailey JR, et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol, 2010; 84, 7018-28. doi:  10.1128/JVI.00548-10
[11] Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol, 2008; 82, 7395-410. doi:  10.1128/JVI.00800-08
[12] Cockerham LR, Hatano H. Elite control of HIV: is this the right model for a functional cure? Trends Microbiol, 2015; 23, 71-5. doi:  10.1016/j.tim.2014.11.003
[13] Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet, 2012; 13, 283-96. https://hal.archives-ouvertes.fr/hal-00679842/document
[14] Colson P, Ravaux I, Tamalet C, et al. HIV infection en route to endogenization: two cases. Clin Microbiol Infect, 2014; 20, 1280-8. doi:  10.1111/1469-0691.12807
[15] Bartha I, McLaren PJ, Brumme C, et al. Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control. PLoS Comput Biol, 2017; 13, e1005339. doi:  10.1371/journal.pcbi.1005339